Ipsen
PharmaParis, France, France · Est. 1929 · 5,800 employees
Ipsen is a global biopharmaceutical company focused on innovative medicines in oncology, neuroscience, and rare diseases.
9
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
225
Clinical Trials↗
All sponsored trials (all statuses)
35
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
9 drugs in development
Phase 31
Phase 23
Preclinical7
By Therapeutic Area
top 4
Oncology
433%
Neurology
325%
Gastroenterology
18%
Immunology
18%
R&D Momentum
68/100
Pipeline Velocity
42/100
Trial Completion Rate
78/100
Pipeline Concentration
25/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 15, 2026
Recruiting
A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of IPN10200 in the Improvement of the Appearance of Moderate To Severe Glabellar Lines in Adult Chinese Participants
Sep 11, 2026
Active, not recruiting
CARBUR: A National, Multicentre, Non-interventional, Prospective, Longitudinal Study to Assess CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity in Routine Clinical Practice.
Sep 10, 2026
Active, not recruiting
A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants
Sep 10, 2026
Recruiting
A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication
Sep 9, 2026
Active, not recruiting
A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults
Sep 9, 2026
Active, not recruiting
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults
Sep 9, 2026
Recruiting
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants
3 more events
Sep 5, 2026TrialA Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity
Sep 5, 2026TrialA Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Chronic Migraine in Adult Participants
Sep 4, 2026TrialAn Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
Details
Company Info
Company Overview
$13.5B
Mkt Cap
$3.6B
Revenue
—
Cash
CEOKamel Chenaoui
Founded1929
Employees5,800
HQParis, France, France
Websiteipsen.com
LinkedInCompany Page
Therapeutic Focus
OncologyNeuroscienceGastroenterologyRare Diseases
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology
Immunology
Neurology
Gastroenterology
Immunology
Neurology
Oncology
Solid Tumor
IPN01195Preclinical
Unknown / Other
Moderate to Severe Upper Facial Lines
CorabotasePreclinical
DysportPreclinical
Showing 15 of 18 programs
Regulatory
Regulatory Timeline
20051 event
FDAAug 30
INCRELEX — INCRELEX
Application BLA021839 (BLA)
20211 event
FDAJul 20
Bylvay — BYLVAY
Application NDA215498 (NDA)
20231 event
FDAAug 16
Sohonos — SOHONOS
Application NDA215559 (NDA)
20241 event
FDAJun 10
Iqirvo — IQIRVO
Application NDA218860 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)